Acts as an agonist of neurotensin receptors. It binds to human neurotensin type 1 receptor (NTSR1), rat neurotensin types 1 and 2 receptors (NTSR1/NTSR2) and mouse neurotensin type 3 receptor (SORT1). Expressed by the venom duct. O-glycosylated. The glycosylation seems to enhance the affinity to the neurotensin receptors. Is under phase II clinical trials under the name CGX-1160 by Cognetix Inc. It is efficacious in a wide range of preclinical pain models (acute, post-surgical, inflammatory, and neuropathic), and is particularly efficacious in models of chronic pain. The mature peptide does not contain cysteine residue. Belongs to the conotoxin C superfamily.